If forecasts prove accurate 2023 could be the biggest year for blockbuster launches for some time.
Breakeven beckons for Amylyx.
A crucial pivotal readout is approaching for the Belgian developer and Vyvgart, in a rare disease that represents the group’s riskiest move yet.
With $219bn in accumulated sales the Abbvie mega-blockbuster is biopharma’s best-selling drug. Can Keytruda do better?